IL27 and pachyonychia congenita: Immunocompetent models of PC may provide insight into whether targeting IL30 in the context of combination therapy may reverse the disappointing results (presented at the ESMO Congress 2023) achieved in the latest clinical trials with Sipuleucel-T (Provenge®), the autologous dendritic cell vaccine, or with Pembrolizumab, the humanized anti-PD-1 monoclonal Ab, both of which are FDA-approved for the treatment of metastatic castration-resistant PC (https://dailyreporter.esmo.org/esmo-congress-2023/genitourinary-cancers).